Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review

Suqi Zhu,Yahan Yu,Mingqi Yang,Xin Liu,Mingkai Lai,Jieren Zhong,Xiaoguang Zhao,Ligong Lu,Yanyan Liu
DOI: https://doi.org/10.1080/14737140.2024.2346624
2024-04-25
Expert Review of Anticancer Therapy
Abstract:Introduction The incidence of primary liver cancer (PLC) has experienced a significant global increase, primarily attributed to the rise in hepatocellular carcinoma (HCC). Unfortunately, HCC is often diagnosed in advanced stages, leaving patients with limited treatment options. Therefore, transformation therapy is a crucial approach for long-term survival and radical resection in patients with advanced HCC. Conversion therapy has demonstrated promise in the treatment of advanced HCC. When integrated with the FOLFOX regimen, hepatic artery infusion chemotherapy (HAIC) can significantly improve tumor response efficiency, leading to high conversion and resection rates.
oncology
What problem does this paper attempt to address?